title: Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.
authors.forename: Katja
authors.initials: K
authors.lastname: Sockel
authors.forename: Martin
authors.initials: M
authors.lastname: Wermke
authors.forename: Jörgen
authors.initials: J
authors.lastname: Radke
authors.forename: Alexander
authors.initials: A
authors.lastname: Kiani
authors.forename: Markus
authors.initials: M
authors.lastname: Schaich
authors.forename: Martin
authors.initials: M
authors.lastname: Bornhäuser
authors.forename: Gerhard
authors.initials: G
authors.lastname: Ehninger
authors.forename: Christian
authors.initials: C
authors.lastname: Thiede
authors.forename: Uwe
authors.initials: U
authors.lastname: Platzbecker
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation; D018365:Neoplasm, Residual; D009687:Nuclear Proteins / Q000235:genetics*; D000090243:Nucleophosmin; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D000090243:Nucleophosmin; D001374:Azacitidine